Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets

Anton Bespalov¹, Thomas Steckler², Bruce Altevogt³, Elena Koustova⁴, Phil Skolnick⁴, Daniel Deaver⁵, Mark J Millan⁶, Jesper F Bastlund⁷, Dario Doller⁸, Jeffrey Witkin⁹, Paul Moser¹⁰, Patricio O'Donnell¹¹, Ulrich Ebert¹², Mark A Geyer¹³, Eric Prinssen¹⁴, Theresa Ballard¹⁴, Malcolm Macleod¹⁵

Affiliations

¹ Neuroscience Research, AbbVie, 6706 Ludwigshafen, Germany. Present address: Partnership for Assessment and Accreditation of Scientific Practice, Am Aukopf 14/1, D-69118 Heidelberg, Germany and Institute of Pharmacology, Pavlov Medical University, 197022 St Petersburg, Russia.
² Janssen Research and Development, B-2340 Beerse, Belgium.
³ Global Policy and International Public Affairs, Pfizer, New York, 10017 New York, USA.
⁴ National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland 20892, USA.
⁵ Non-Clinical Research and Development, Alkermes, Waltham, Massachusetts 02451, USA.
⁶ Institut de Recherche Servier, 78290 Croissy sur Seine, France.
⁷ Neuroscience Research, H. Lundbeck A/S, Copenhagen, 2500 Valby, Denmark.
⁸ Discovery Chemistry &DMPK; Lundbeck Research USA, Paramus, New Jersey 07652, USA. Present address: Concert Pharmaceuticals, Inc., 99 Hayden Avenue, Lexington, Massachusetts 02421, USA.
⁹ Neuroscience Discovery Research, Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
¹⁰ Pierre Fabre Research Institute, 81106 Castres, France. Present address: BIAL-Portela &Ca S.A., Avenida da Siderurgia Nacional, 4745-457 São Mamede do Coronado, Portugal.
¹¹ Neuroscience and Pain Research Unit, Pfizer, Cambridge, Massachusetts 02139, USA.
¹² Boehringer Ingelheim Pharma, 55218 Ingelheim am Rhein, Germany.
¹³ University of California San Diego, La Jolla, California 92093, USA.
¹⁴ Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, CH-4070 Basel, Switzerland.
¹⁵ Edinburgh University, Old College, South Bridge, Edinburgh EH8 9YL, UK.

PMID: 27312728
DOI: 10.1038/nrd.2016.88

Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets

Anton Bespalov et al. Nat Rev Drug Discov. 2016 Jul.

. 2016 Jul;15(7):516.

doi: 10.1038/nrd.2016.88. Epub 2016 Jun 17.

Authors

Affiliations

¹ Neuroscience Research, AbbVie, 6706 Ludwigshafen, Germany. Present address: Partnership for Assessment and Accreditation of Scientific Practice, Am Aukopf 14/1, D-69118 Heidelberg, Germany and Institute of Pharmacology, Pavlov Medical University, 197022 St Petersburg, Russia.
² Janssen Research and Development, B-2340 Beerse, Belgium.
³ Global Policy and International Public Affairs, Pfizer, New York, 10017 New York, USA.
⁴ National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland 20892, USA.
⁵ Non-Clinical Research and Development, Alkermes, Waltham, Massachusetts 02451, USA.
⁶ Institut de Recherche Servier, 78290 Croissy sur Seine, France.
⁷ Neuroscience Research, H. Lundbeck A/S, Copenhagen, 2500 Valby, Denmark.
⁸ Discovery Chemistry &DMPK; Lundbeck Research USA, Paramus, New Jersey 07652, USA. Present address: Concert Pharmaceuticals, Inc., 99 Hayden Avenue, Lexington, Massachusetts 02421, USA.
⁹ Neuroscience Discovery Research, Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
¹⁰ Pierre Fabre Research Institute, 81106 Castres, France. Present address: BIAL-Portela &Ca S.A., Avenida da Siderurgia Nacional, 4745-457 São Mamede do Coronado, Portugal.
¹¹ Neuroscience and Pain Research Unit, Pfizer, Cambridge, Massachusetts 02139, USA.
¹² Boehringer Ingelheim Pharma, 55218 Ingelheim am Rhein, Germany.
¹³ University of California San Diego, La Jolla, California 92093, USA.
¹⁴ Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, CH-4070 Basel, Switzerland.
¹⁵ Edinburgh University, Old College, South Bridge, Edinburgh EH8 9YL, UK.

PMID: 27312728
DOI: 10.1038/nrd.2016.88

No abstract available

PubMed Disclaimer

References

1. Drug Discov Today. 2012 May;17(9-10):419-24 - PubMed
1. Amyotroph Lateral Scler. 2008;9(1):4-15 - PubMed
1. PLoS Med. 2010 Mar 30;7(3):e1000245 - PubMed
1. Eur Neuropsychopharmacol. 2015 Oct;25(10):1803-7 - PubMed
1. PLoS Med. 2005 Aug;2(8):e124 - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

NC/L000970/1/NC3RS_/National Centre for the Replacement, Refinement and Reduction of Animals in Research/United Kingdom

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets

Affiliations

Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets

Authors

Affiliations

References

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical